INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAB4. A total of 10 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2023. The put-call ratio across all filers is - and the average weighting 0.6%.
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| PenderFund Capital Management Ltd. | 11,795,000 | $12,609 | 3.92% |
| Context Capital Management, LLC | 20,230 | $16,269 | 1.47% |
| DG Capital Management, LLC | 1,101,000 | $882,925 | 0.39% |
| OAKTREE CAPITAL MANAGEMENT LP | 11,824,000 | $9,508,858 | 0.12% |
| GABELLI & Co INVESTMENT ADVISERS, INC. | 225,000 | $179,910 | 0.03% |
| Calamos Advisors LLC | 5,000,000 | $3,998,350 | 0.02% |
| FRANKLIN RESOURCES INC | 21,000,000 | $16,888,196 | 0.01% |
| Russell Investments Group, Ltd. | 2,676,000 | $2,146,735 | 0.00% |
| UBS ASSET MANAGEMENT AMERICAS INC | 3,000,000 | $2,481,591 | 0.00% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |
This page lists INTERCEPT PHARMACEUTICALS IN's shareholders in Q2 2023. To view INTERCEPT PHARMACEUTICALS IN's shareholder history, click here.